FASLODEX® (fulvestrant) logo  Medicines

  • This site is intended for US Health Care Professionals

  • Go to Patient Site
  • IMPORTANT SAFETY INFORMATION
  • PRESCRIBING INFORMATION
  • REQUEST A REP

  • AZ Connect
  • AZ Professional Sites
  • AZ Medical Information Support
  • Important Safety Information
  • Prescribing Information

  • ASTRAZENECA ACCESS 360™ REIMBURSEMENT SUPPORT

HEALTH CARE PROFESSIONAL REQUEST FOR REPRESENTATIVE

To send your request to the US Information Center at AstraZeneca, please fill out the form below. The information you submit will be governed by our Privacy Notice.
The fields marked with an asterisk (*) are mandatory.

How can we help you?

If you would like information regarding products from AstraZeneca, please call 1-800-236-9933, Monday through Friday, 8:30 AM to 8:30 PM ET, excluding holidays.

US-22344 Last Updated 9/18

Thank you

  • FASLODEX® (fulvestrant) logo
  • Combination Therapy
  • Monotherapy
  • Dosing & Administration
  • MOD & MOA
  • ASTRAZENECA ACCESS 360™ REIMBURSEMENT SUPPORT
  • More Hide

    SITE MAP

    • Home

    • Combination Therapy

      • PALOMA-3 Trial setup
      • Efficacy Results
      • Safety Data
      • MONARCH 2 Trial setup
      • Efficacy Results
      • Safety Data
    • Monotherapy

      • FALCON Trial Setup
      • Efficacy Results
      • Safety Data
      • CONFIRM Trial setup
      • Efficacy Results
      • Safety Data
    • Dosing & Administration

    • MOD & MOA

    • ASTRAZENECA ACCESS 360™ REIMBURSEMENT SUPPORT

    Read More Read Less

    Important Safety Information About FASLODEX

    Contraindications

    • FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to any of its components. Hypersensitivity reactions, including urticaria and angioedema, have been reported in association with FASLODEX

    Risk of Bleeding

    • Because FASLODEX is administered intramuscularly, it should be used with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use

    Hepatic Impairment

    • FASLODEX is metabolized primarily in the liver. A 250 mg dose is recommended in patients with moderate hepatic impairment (Child-Pugh class B). FASLODEX has not been evaluated in patients with severe hepatic impairment (Child-Pugh class C)

    Injection Site Reaction

    • Use caution while administering FASLODEX at the dorsogluteal injection site due to the proximity of the underlying sciatic nerve. Injection site–related events, including sciatica, neuralgia, neuropathic pain, and peripheral neuropathy, have been reported with FASLODEX injection

    Embryo-Fetal Toxicity and Lactation

    • Advise pregnant women of the potential risk to a fetus. Advise women of reproductive potential to use effective contraception during FASLODEX treatment and for 1 year after the final dose. Advise lactating women not to breastfeed during treatment with FASLODEX and for 1 year after the final dose because of the potential risk to the infant

    Immunoassay Measurement of Serum Estradiol

    • Due to structural similarity of fulvestrant and estradiol, FASLODEX can interfere with estradiol measurement by immunoassay, resulting in falsely elevated estradiol levels

    Adverse Reactions

    Monotherapy

    • The most common adverse reactions occurring in ≥5% of patients receiving FASLODEX 500 mg were injection site pain, nausea, bone pain, arthralgia, headache, back pain, fatigue, pain in extremity, hot flash, myalgia, vomiting, anorexia, diarrhea, asthenia, musculoskeletal pain, cough, dyspnea, and constipation
    • Increased hepatic enzymes (ALT, AST, ALP) occurred in >15% of FASLODEX patients and were not dose-dependent

    Combination Therapy—FASLODEX plus palbociclib

    • The most frequently reported Grade ≥3 adverse reactions in patients receiving FASLODEX plus palbociclib in descending frequency were neutropenia and leukopenia
    • Adverse reactions (≥10%) of any grade reported in patients receiving FASLODEX 500 mg plus palbociclib 125 mg/day by descending frequency were neutropenia, leukopenia, infections, fatigue, nausea, anemia, stomatitis, diarrhea, thrombocytopenia, vomiting, alopecia, rash, decreased appetite, and pyrexia
    • Additional adverse reactions occurring at an overall incidence of <10% of patients receiving FASLODEX plus palbociclib included asthenia, aspartate aminotransferase increased, dysgeusia, epistaxis, lacrimation increased, dry skin, alanine aminotransferase increased, vision blurred, dry eye, and febrile neutropenia

    Combination Therapy—FASLODEX plus abemaciclib

    • The most frequently reported (≥5%) Grade 3 or 4 adverse reactions in patients receiving FASLODEX plus abemaciclib were neutropenia, diarrhea, leukopenia, anemia, and infections
    • The most common adverse reactions (≥20%) of any grade reported in patients receiving FASLODEX 500 mg plus abemaciclib 150 mg twice daily were diarrhea, fatigue, neutropenia, nausea, infections, abdominal pain, anemia, leukopenia, decreased appetite, vomiting, and headache

    Indications for FASLODEX

    Monotherapy

    FASLODEX is an estrogen receptor antagonist indicated for the:

    • Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy
    • Treatment of HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy

    Combination Therapy

    • FASLODEX in combination with palbociclib or abemaciclib is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in women with disease progression after endocrine therapy

    Please see full Prescribing Information for FASLODEX with Patient Information.

    You may report side effects related to AstraZeneca products by clicking here.

    Back to top

    Important Safety Information About FASLODEX

    Contraindications

    • FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to any of its components. Hypersensitivity reactions, including urticaria and angioedema, have been reported in association with FASLODEX

    Risk of Bleeding

    • Because FASLODEX is administered intramuscularly, it should be used with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use

    Hepatic Impairment

    • FASLODEX is metabolized primarily in the liver. A 250 mg dose is recommended in patients with moderate hepatic impairment (Child-Pugh class B). FASLODEX has not been evaluated in patients with severe hepatic impairment (Child-Pugh class C)

    Injection Site Reaction

    • Use caution while administering FASLODEX at the dorsogluteal injection site due to the proximity of the underlying sciatic nerve. Injection site–related events, including sciatica, neuralgia, neuropathic pain, and peripheral neuropathy, have been reported with FASLODEX injection

    Embryo-Fetal Toxicity and Lactation

    • Advise pregnant women of the potential risk to a fetus. Advise women of reproductive potential to use effective contraception during FASLODEX treatment and for 1 year after the final dose. Advise lactating women not to breastfeed during treatment with FASLODEX and for 1 year after the final dose because of the potential risk to the infant

    Immunoassay Measurement of Serum Estradiol

    • Due to structural similarity of fulvestrant and estradiol, FASLODEX can interfere with estradiol measurement by immunoassay, resulting in falsely elevated estradiol levels

    Adverse Reactions

    Monotherapy

    • The most common adverse reactions occurring in ≥5% of patients receiving FASLODEX 500 mg were injection site pain, nausea, bone pain, arthralgia, headache, back pain, fatigue, pain in extremity, hot flash, myalgia, vomiting, anorexia, diarrhea, asthenia, musculoskeletal pain, cough, dyspnea, and constipation
    • Increased hepatic enzymes (ALT, AST, ALP) occurred in >15% of FASLODEX patients and were not dose-dependent

    Combination Therapy—FASLODEX plus palbociclib

    • The most frequently reported Grade ≥3 adverse reactions in patients receiving FASLODEX plus palbociclib in descending frequency were neutropenia and leukopenia
    • Adverse reactions (≥10%) of any grade reported in patients receiving FASLODEX 500 mg plus palbociclib 125 mg/day by descending frequency were neutropenia, leukopenia, infections, fatigue, nausea, anemia, stomatitis, diarrhea, thrombocytopenia, vomiting, alopecia, rash, decreased appetite, and pyrexia
    • Additional adverse reactions occurring at an overall incidence of <10% of patients receiving FASLODEX plus palbociclib included asthenia, aspartate aminotransferase increased, dysgeusia, epistaxis, lacrimation increased, dry skin, alanine aminotransferase increased, vision blurred, dry eye, and febrile neutropenia

    Combination Therapy—FASLODEX plus abemaciclib

    • The most frequently reported (≥5%) Grade 3 or 4 adverse reactions in patients receiving FASLODEX plus abemaciclib were neutropenia, diarrhea, leukopenia, anemia, and infections
    • The most common adverse reactions (≥20%) of any grade reported in patients receiving FASLODEX 500 mg plus abemaciclib 150 mg twice daily were diarrhea, fatigue, neutropenia, nausea, infections, abdominal pain, anemia, leukopenia, decreased appetite, vomiting, and headache

    Indications for FASLODEX

    Monotherapy

    FASLODEX is an estrogen receptor antagonist indicated for the:

    • Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy
    • Treatment of HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy

    Combination Therapy

    • FASLODEX in combination with palbociclib or abemaciclib is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in women with disease progression after endocrine therapy

    Please see full Prescribing Information for FASLODEX with Patient Information.

    You may report side effects related to AstraZeneca products by clicking here.

    Back to top

    Read More Read Less

    AstraZeneca Medicines

    AstraZeneca Pharmaceutical Company
    AstraZeneca Pharmaceutical Company


    • Contact Us
    • US Corporate Site
    • Privacy Notice
    • Cookie Notice
    • Legal Statement
    • Site Map
    • Prescribing Information

    This product information is intended for US Health Care Professionals only.

    FASLODEX is a registered trademark and AstraZeneca Access 360 is a trademark of the AstraZeneca group of companies.

    ©2018 AstraZeneca. All rights reserved. US-22344 Last Updated 9/18
    Back to top